Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58718) - R7 - Effective June 25, 2026

Date Posted: June 25, 2026

This Billing and Coding Article has been revised under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: May 11, 2026

Summary of Changes:

Under CPT/HCPCS Codes Group 1: Paragraph added "ExoDX Prostate assay (PLA 0005U), performed on non-DRE urine specimens". Under CPT/HCPCS Codes Group 1: Codes added 0005U. Under CPT/HCPCS Codes Group 2: Paragraph added "ExoDX Prostate assay (PLA 0005U), performed on non-DRE urine specimens". Under CPT/HCPCS Codes Group 2: Codes added 0005U. This revision is effective 5/11/2026.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Jun 25 , 2026